The 4th Liquid Biopsy for Precision Oncology East Coast Summit returns to Boston with a refreshed agenda, sharpened focus, ...

European Valuations and Interpath Advisory Limited, acting on behalf of the liquidators of Surepharm Services Limited, is ...

TIGIT, in particular, has proved to be a tricky target for drug developers, and BeiGene's decision comes just a few months ...

The EMA has called a temporary halt to a phase 2 trial of Sarepta's Roche-partnered Duchenne muscular dystrophy (DMD) gene ...

The agreement with the GKV-Spitzenverband – the national association of statutory health insurance funds – means that Hemgenix (etranacogene dezaparvovec) can now be reimbursed across Germany's health ...

Vanrafia (atrasentan) is the first drug in the selective endothelin A receptor antagonist (ERA) class to be cleared in the US ...

Pharmaceuticals are exempt from the cascade of 'Liberation Day' tariffs revealed by President Donald Trump – for now – but ...

Traditional DCTs primarily focus on prospective data collection, adapting interventional research processes to virtual approaches and providing an incomplete picture of patients. This approach offers ...

Raising awareness of the risk of post-traumatic hypopituitarism following a head injury must be increased among healthcare professionals, say campaigners. Thousands of people, in the UK alone ...

Having a blueprint for supply chain resiliency is critical, as a mature and robust risk programme enables the right emergency ...

Takeda's Adcetris has become the first drug recommended for routine NHS use as a treatment for previously untreated ...

The latest rejection looks set to mark the end of J&J's drive to resolve the litigation through the bankruptcy courts, as the ...